AstraZeneca: a sweet spot on FTSE 100 index.
(CercleFinance.com) - Shares of AstraZeneca were slightly up on Monday after Credit Suisse upgraded the stock from "neutral" to "outperform," while increasing its target price from 4,800 pence to 5,800 pence .
"Following recent pipeline success for Tagrisso and Imfinzi, we see a marked improvement in AstraZeneca's strategic position in pricing power and replacement power," the broker said.
Shares in AstraZeneca are currently up 0.4% at 5,146 pence compared to a 0.1% rise in the London FTSE 100 index.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
"Following recent pipeline success for Tagrisso and Imfinzi, we see a marked improvement in AstraZeneca's strategic position in pricing power and replacement power," the broker said.
Shares in AstraZeneca are currently up 0.4% at 5,146 pence compared to a 0.1% rise in the London FTSE 100 index.
Copyright (c) 2017 CercleFinance.com. All rights reserved.